In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics ...

The direct-to-consumer (DTC) genetic testing market is projected to grow at a CAGR of ~12% over the forecast period. Major ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with ...

Institutional investors own 99.02% of the company’s stock. Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian ...